SCHEMBL2651934

SCHEMBL2651934

CC(C)(O)c1cccc(-c2n[c]c[nH]2)c1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.36
KCNH2 Q12809 1/20 0.36
SCN2A Q99250 2/20 0.36
SYK P43405 1/20 0.36
KIF11 P52732 1/20 0.35
CYP17A1 P05093 3/20 0.35
CYP3A4 P08684 3/20 0.35
PIN1 Q13526 1/20 0.34
HRH1 P35367 1/20 0.33
HRH4 Q9H3N8 1/20 0.33
CTSA P10619 1/20 0.32
RXRA P19793 2/20 0.32
RXRB P28702 2/20 0.32
CYP4F2 P78329 1/20 0.32
CYP4A11 Q02928 1/20 0.32
IKBKB O14920 1/20 0.31
BRD4 O60885 1/20 0.31
CREBBP Q92793 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2095585 0.88 KIF11 (0.47) SCN2AKIF11CYP3A4PIN1RXRA
SCHEMBL4015570 0.81 SCN2A (0.55) SCN2ACYP3A4PIN1HRH1HRH4
SCHEMBL4041568 0.76 HSD17B1 (0.47) CYP3A4
SCHEMBL2091213 0.76 IDO1 (0.45) PIN1
SCHEMBL548600 0.74 KIF11 (0.50) NR4A2KCNH2SYKKIF11CYP17A1
SCHEMBL5183474 0.74 NISCH (0.51) NR4A2KCNH2SCN2ASYKKIF11
SCHEMBL2650383 0.72 IDO1 (0.49) SCN2APIN1HRH1
SCHEMBL4049207 0.72 ALDH1A1 (0.47) HRH1HRH4IKBKB
SCHEMBL403894 0.70 MTOR (0.43) SCN2ACYP3A4
SCHEMBL548430 0.69 RXRA (0.53) NR4A2KCNH2SYKKIF11CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1635813-A4 COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA MERCK & CO INC (US) 2009-07-01 EP disclosed
EP-1799241-A2 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY Merck & Co., Inc. (US) 2007-06-27 EP disclosed
WO-2006036770-A2 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY MERCK & CO., INC. (US) 2006-04-06 WO disclosed
EP-1635832-A2 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES Merck & Co., Inc. (US) 2006-03-22 EP disclosed
EP-1635813-A2 COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA Merck & Co. Inc. (US) 2006-03-22 EP disclosed
EP-1635773-A2 COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION Merck & Co., Inc. (a New Jersey corp.) (US) 2006-03-22 EP disclosed
WO-2005000217-A2 COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA MERCK & CO., INC. (US) 2005-01-06 WO disclosed
WO-2004110375-A2 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES MERCK & CO., INC. (US) 2004-12-23 WO disclosed
WO-2004110368-A2 COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION MERCK & CO., INC. (US) 2004-12-23 WO disclosed
EP-1204663-A1 NOVEL SPIRO COMPOUNDS BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-15 EP disclosed
WO-2001014376-A1 NOVEL SPIRO COMPOUNDS BANYU PHARMACEUTICAL CO., LTD. (JP) 2001-03-01 WO disclosed